Latest News

Image credit: Ban | stock.adobe.com
Four-Year Data from Long-Term Extension Trial Show Efficacy of Sotyktu Treating Moderate-to-Severe Plaque Psoriasis

May 17th 2024

Sotyktu (deucravacitinib; Bristol Myers Squibb) is an oral, selective, allosteric tyrosine kinase 2 inhibitor that produced clinically meaningful improvements in Psoriasis Area and Severity Index scores among adult patients with moderate-to-severe plaque psoriasis.

Putting LP-284 on the Industry RADR
Putting LP-284 on the Industry RADR

May 17th 2024

The Future of RBQM Adoption
The Future of RBQM Adoption

May 17th 2024

Image credit: 9dreamstudio | stock.adobe.com
Roche's Novel Dual GLP-1/GIP Receptor Agonist Produces Clinically Meaningful Weight Loss in Phase Ib Trial

May 16th 2024

Where Innovation and Patients Meet to Improve Cancer Care
Where Innovation and Patients Meet to Improve Cancer Care

May 16th 2024

Conference Coverage

View All
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials

February 19th 2024

SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials
SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials

February 14th 2024

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

February 13th 2024

SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden

February 13th 2024

Latest Videos
Podcasts
© Alex from the Rock - © Alex from the Rock - stock.adobe.com
Rinol Alaj, Jaclyn Patterson, Applied Clincial Trials Podcast

All News

© 2024 MJH Life Sciences

All rights reserved.